Strs Ohio Acquires Shares of 11,000 Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Strs Ohio has acquired 11,000 shares of Supernus Pharmaceuticals, valued at approximately $360,000, signaling increased institutional interest in the company.
• Several analysts have recently upgraded Supernus Pharmaceuticals' stock rating, with a consensus price target of $43.00 indicating optimism about future performance.
• Insider transactions show significant selling activity, with a total of 263,093 shares sold over the past three months, raising questions about future stock performance.

Strs Ohio bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,000 shares of the specialty pharmaceutical company's stock, valued at approximately $360,000.

Other hedge funds have also made changes to their positions in the company. Financial Management Professionals Inc. acquired a new position in Supernus Pharmaceuticals in the 1st quarter valued at $30,000. Versant Capital Management Inc increased its position in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $42,000. Caitong International Asset Management Co. Ltd purchased a new position in Supernus Pharmaceuticals during the first quarter worth about $41,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Supernus Pharmaceuticals in the 1st quarter valued at about $46,000.

Analysts Set New Price Targets

A number of analysts have recently issued reports on SUPN shares. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Piper Sandler raised their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research note on Friday, August 29th. Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. Finally, Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $43.00.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 5,369 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Timothy C. Dec sold 11,780 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares of the company's stock, valued at $55,434.54. This represents a 90.43% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 263,093 shares of company stock valued at $11,476,065 over the last three months. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $46.83 on Wednesday. The stock has a 50-day simple moving average of $41.20 and a 200-day simple moving average of $35.27. The stock has a market cap of $2.63 billion, a P/E ratio of 40.72 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $47.65.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.